Developing infrared spectroscopic detection for stratifying brain tumour patients : glioblastoma multiforme vs. lymphoma

Cameron, James M. and Butler, Holly J. and Smith, Benjamin R. and Hegarty, Mark G. and Jenkinson, Michael D. and Syed, Khaja and Brennan, Paul M. and Ashton, Katherine and Dawson, Timothy and Palmer, David S. and Baker, Matthew J. (2019) Developing infrared spectroscopic detection for stratifying brain tumour patients : glioblastoma multiforme vs. lymphoma. Analyst. ISSN 0003-2654 (In Press)

[img] Text (Cameron-etal-Analyst-2019-Developing-infrared-spectroscopic-detection-for-stratifying-brain-tumour-patients)
Cameron_etal_Analyst_2019_Developing_infrared_spectroscopic_detection_for_stratifying_brain_tumour_patients.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 7 October 2020.

Download (2MB) | Request a copy from the Strathclyde author

    Abstract

    Over a third of brain tumour patients visit their general practitioner more than five times prior to diagnosis in the UK, leading to 62% of patients being diagnosed as emergency presentations. Unfortunately, symptoms are non-specific to brain tumours, and the majority of these patients complain of headaches on multiple occasions before being referred to a neurologist. As there are currently no methods in place for the early detection of brain cancer, the affected patients’ average life expectancy is reduced by 20 years. These statistics indicate that the current pathway is ineffective, and there is a vast need for a rapid diagnostic test. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy is sensitive to the hallmarks of cancer, as it analyses the full range of macromolecular classes. The combination of serum spectroscopy and advanced data analysis has previously been shown to rapidly and objectively distinguish brain tumour severity. Recently, a novel high-throughput ATR accessory has been developed, which could be cost-effective to the National Health Service in the UK, and valuable for clinical translation. In this study, 765 blood serum samples have been collected from healthy controls and patients diagnosed with various types of brain cancer, contributing to one of the largest spectroscopic studies to date. Three robust machine learning techniques - random forest, partial least squares-discriminant analysis and support vector machine - have all provided promising results. The novel high-throughput technology has been validated by separating brain cancer and non-cancer with balanced accuracies of 90% which is comparable to the traditional fixed diamond crystal methodology. Furthermore, the differentiation of brain tumour type could be useful for neurologists, as some are difficult to distinguish through medical imaging alone. For example, the highly aggressive glioblastoma multiforme and primary cerebral lymphoma can appear similar on magnetic resonance imaging (MRI) scans, thus are often misdiagnosed. Here, we report the ability of infrared spectroscopy to distinguish between glioblastoma and lymphoma patients, at a sensitivity and specificity of 90.1% and 86.3%, respectively. A reliable serum diagnostic test could avoid the need for surgery and speed up time to definitive chemotherapy and radiotherapy.